Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2019-08-14 Interim / Quarterly Rep…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
2nd quarter and first half 2018 report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Gentian Diagnostics AS, covering the second quarter and first half of 2019. It includes detailed financial statements (Statement of Comprehensive Income, Statement of Financial Position), management commentary on financial performance, operational status, R&D updates, and shareholder information. It is not an announcement of a report, but the report itself, containing substantive financial data for an interim period. H1 2019
2019-08-14 English
2nd quarter and first half 2018 report
Investor Presentation Classification · 98% confidence The document is titled "Q2 Presentation 2019" and contains detailed financial highlights for the second quarter (2Q19) compared to the previous year (2Q18), including tables for Sales, Revenues, COGS, OPEX, and Cash Flow. It also discusses product performance (Cystatin C, fCAL® turbo) and provides an outlook for the remainder of 2019. This structure—a presentation format summarizing period-specific financial results—is characteristic of an Investor Presentation (IP) or potentially an Earnings Release (ER). Since it includes detailed tables and operational commentary beyond just the key highlights, 'Investor Presentation' (IP) is the most appropriate classification, as it is a presentation deck used to communicate results to investors.
2019-08-14 English
2nd quarter and first half 2018 report
Report Publication Announcement Classification · 96% confidence The document explicitly states it is announcing the '2nd quarter and first half 2018 report' (though the date seems inconsistent, mentioning 2019 results) and provides key financial highlights (sales revenue growth, specific figures). This structure—a brief announcement summarizing key figures for a specific period (quarter/half-year)—is characteristic of an Earnings Release (ER). However, the final sentence states, 'Please find the report and results presentation enclosed.' This suggests the document itself is primarily an announcement *about* the results, rather than the comprehensive report (which would be an IR). Given the content is the initial summary of period results, ER is the most appropriate classification, even though it mentions enclosures. If the document were only the enclosure announcement, RPA would be considered, but the inclusion of the actual highlights points strongly to ER.
2019-08-14 English
Gentian becomes sole reagent supplier in sales channel agreement between Roche and BÜHLMANN for fCAL® turbo
Regulatory Filings Classification · 100% confidence The document is a press release dated August 13, 2019, announcing a 'sales channel agreement' where Gentian becomes the sole reagent supplier for a Roche/BÜHLMANN co-branded test kit. This announcement details a significant business development, partnership, and expected revenue impact, which falls under corporate news or strategic updates. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it describes a major business transaction/agreement that impacts future operations and market reach, it is best classified as a general Regulatory Filing (RNS) as it is a public announcement of material information, or potentially a general corporate announcement not explicitly covered by other codes. Given the options, RNS serves as the best fit for a material, non-standard corporate announcement that isn't a specific financial report or management change.
2019-08-13 English
Gentian becomes sole reagent supplier in sales channel agreement between Roche and BÜHLMANN for fCAL® turbo
Regulatory Filings Classification · 100% confidence The document announces a specific business agreement (sales channel agreement) between Gentian, Roche, and BÜHLMANN regarding the supply of reagents for a diagnostic test (fCAL® turbo). It details the terms, market size, expected revenue impact, and includes a concluding statement: 'Please see the enclosed release for additional information.' This structure—a short announcement detailing a specific corporate event (like a partnership or M&A component) followed by a reference to an 'enclosed release'—strongly suggests this is a general regulatory announcement rather than a comprehensive financial report (like 10-K or IR) or a dedicated M&A filing (TAR). Since it is a specific corporate action announcement that doesn't fit perfectly into categories like DIV, CAP, or DIRS, and given its brevity (2598 chars), it is best classified as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if the 'enclosed release' is the primary document. Given the content is a direct announcement of a commercial agreement, RNS is the most appropriate general regulatory category for non-standard corporate news.
2019-08-13 English
Beckman Coulter and Gentian extend their cooperation in the expanding business in the field of renal testing
Regulatory Filings Classification · 95% confidence The document announces the extension of a cooperation/supply agreement between Gentian Diagnostics and Beckman Coulter regarding renal testing reagents. This is a business development announcement concerning a partnership and supply contract, not a standard regulatory financial filing (like 10-K, IR, ER, or DIV). It does not fit the definitions for AGM-R, AR, MANG, CT, CAP, DVA, DLST, DIRS, SR, XLSX, FS, CGR, IRAT, IP, LTR, TAR, MRQ, NAV, PSI, DEF 14A, RPA, SHA, or POS. Since it is a specific business announcement that doesn't fit the primary financial/regulatory categories, it is best classified as a general Regulatory Filing (RNS), which serves as a fallback for miscellaneous corporate announcements, although 'CAP' (Capital/Financing Update) might be considered if the agreement involved significant financing terms, but the text focuses purely on the supply extension and cooperation. Given the nature of a partnership extension announcement, RNS is the most appropriate general category.
2019-07-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.